This report on antibacterial drugs market studies the current as well as future prospects of the market globally. The market for antibacterial drugs is segmented on the basis of major classes of drugs, namely, aminoglycosides, B-lactams, tetracyclines, sulfonamides, quinolones/fluoroquinolones, macrolides and phenicols.
Albany, NY -- (SBWIRE) -- 06/18/2014 -- The worldwide market for antibacterial drugs is estimated to grow at a CAGR of 0.3% between 2013 and 2019, says Transparency Market Research in its latest published report. The report studies the antibacterial drugs market by class including: Tetracyclines, Quinolones/Fluoroquinolones, Aminoglycosides, Sulfonamides, B-Lactams, Macrolides, Phenicols, and Pipeline drugs
In a recently published report, Transparency Market Research, a U.S.-based market intelligence firm, indicates that the global market for antibacterial drugs is likely to be worth USD 45.09 billion by 2019, growing at a compounded annual growth rate (CAGR) of 0.3% between 2013 and 2019. As of 2012, this market was worth USD 43.55 billion.
The report, titled ‘Antibacterial Drugs Market (By Class - Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/Fluoroquinolones, Macrolides and Phenicols, and Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019,’ can be purchased on Transparency Market Research’s website. http://www.transparencymarketresearch.com/antibacterial-drugs-market.htm
The report provides a holistic view of the antibacterial drugs market by type, respective applications, geographical market, and goes on to offer a complete overview of the leading market players in the antibacterial drugs market in the ‘Company Profiles’ section.
Antibacterial drugs have been in use since the early 20th century beginning with the discovery of penicillin, the first antibiotic, in 1928. Since then, antibacterial drugs have spawned into a multi-million dollar market with every new discovery and novel application.
Antibacterial drugs are primarily utilized in the treatment of infectious diseases that are caused by different types of bacteria including: gram negative, gram positive, anaerobic and aerobic. While other diseases can be treated using alternative or substitute methodologies, the same isn’t true for bacteria-related infectious diseases. Much of the demand for antibacterial drugs is hinged on this exclusive dependence for human healthcare.
There are seven major classifications of antibacterial drugs. These include: Tetracyclines, Quinolones/Fluoroquinolones, Aminoglycosides, Sulfonamides, B-Lactams, Macrolides, Phenicols, and other drugs that are in the pipeline.
According to the findings of the report, the largest class within the antibacterial drugs market as of 2012 was the B-lactams class, comprising a 57% of the market. The second largest class was that of Quinolones constituting a 16.6% share of the worldwide market in 2012, but is expected to show a negative CAGR during the report’s forecast period as several patent expiries will likely erode sales and a number of drug-resistant strains of bacteria develop. Furthermore, concerns about the side effects of these drugs have been expressed after reports of tendon damage and tendon ruptures.
On the other hand, the report states that the demand for other classes such as quinolones/fluoroquinolones and macrolides will remain high during the period of the forecast, given their importance in treating a wide range of bacterial infections. The market for this class of drugs will also be benefit from the fact that a number of new drugs are in the pipeline and are expected to launch over the forecast period (between 2013 and 2019).
The report also analyzes the demand and potential of antibacterial drugs in the emerging economies of Latin America, Asia-Pacific, Africa, and the Middle East. Here, the affordability and efficacy of such drugs will drive the market. At the same time, a rising population of the aged worldwide will be-to some extent-responsible for the growth of the global market for antibacterial drugs.
Another critical factor that will contribute to a consistent demand for antibacterial drugs is the emergence of resistant bacteria that necessitates the development of innovative drug molecules.
As of 2012, the largest share, by revenue generated, was held by Asia-Pacific and the region is projected to see the highest rate of growth over the period of forecast mainly due to the prevalence of a large infected population, including those affected by tetanus, tuberculosis, and pneumonia.
The report goes on to look at the critical future trends and opportunities in the global antibacterial drug market, besides offering a complete lowdown on key market players operating within this industry.
For Press Release : http://www.transparencymarketresearch.com/pressrelease/antibacterial-drugs-market.htm
Antibacterial Drugs Market, by Class
Antibacterial Drugs Market, by Geography
- North America
- Rest of the World (RoW)
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.